Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Carfilzomib in Multiple Myeloma

Associating dosage with response

Publish date:: September 23, 2015

There is a dose-response relationship between the administered dose of carfilzomib and efficacy, according to a study of 461 patients with relapsed and/or refractory multiple myeloma. Researchers found:

• Adjustment for cohort and baseline covariates produced an odds ratio for overall response rate of 1.28 for each 1 mg/m² increase in the average administered dose of carfilzomib, up to 27 mg/m².

• Qualitatively similar and statistically significant results were seen for the association between administered dose and cycle-specific response status, duration of response, time to progression, progression-free survival, and overall survival.

Citation: Squifflet P, Michiels, S, Siegel D, et al. Relationship between carfilzomib dose and efficacy outcomes in patients with relapsed and/or refractory multiple myeloma. [Published online ahead of print September 18, 2015]. Clin Lymphoma Myeloma Leuk. doi: http://dx.doi.org/10.1016/j.clml.2015.09.005.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Must Reads in Multiple Myeloma

Caregiver burden of outpatient ASCT for multiple myeloma comparable with inpatient transplant,

Study found dual-targeted CAR T highly active against relapsed/refractory multiple myeloma,

Durable responses with anti-BCMA CAR T-cell for multiple myeloma,

Circulating miRNA could be a potential biomarker for early diagnosis of MM,